Suraj Kalia
Stock Analyst at Oppenheimer
(3.35)
# 964
Out of 4,650 analysts
78
Total ratings
50%
Success rate
3.62%
Average return
Main Sectors:
Stocks Rated by Suraj Kalia
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TMDX TransMedics Group | Maintains: Outperform | $200 → $125 | $88.00 | +42.04% | 8 | Oct 29, 2024 | |
| ABT Abbott Laboratories | Initiates: Outperform | $130 | $114.27 | +13.77% | 1 | Oct 8, 2024 | |
| TLSI TriSalus Life Sciences | Initiates: Outperform | $10 | $3.95 | +153.16% | 1 | Sep 16, 2024 | |
| EW Edwards Lifesciences | Maintains: Outperform | $90 | $70.58 | +27.51% | 5 | Sep 12, 2024 | |
| AORT Artivion | Maintains: Outperform | $25 → $30 | $26.53 | +13.08% | 2 | Aug 9, 2024 | |
| NYXH Nyxoah | Maintains: Outperform | $15 → $13 | $9.54 | +36.27% | 4 | Aug 7, 2024 | |
| IRTC iRhythm Technologies | Maintains: Outperform | $165 → $145 | $76.15 | +90.41% | 4 | Aug 2, 2024 | |
| ITGR Integer Holdings | Initiates: Outperform | $135 | $128.21 | +5.30% | 1 | Jul 16, 2024 | |
| RMD ResMed | Downgrades: Perform | n/a | $247.76 | - | 6 | Jun 25, 2024 | |
| ATRC AtriCure | Upgrades: Outperform | $32 | $29.10 | +9.97% | 5 | Apr 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $5.19 | - | 8 | Feb 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $42 → $30 | $13.21 | +127.10% | 5 | Nov 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $70 | $87.87 | -20.33% | 1 | Sep 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $30 | $14.47 | +107.33% | 5 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $10 | $0.46 | +2,073.91% | 1 | Jun 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $97 | $86.60 | +12.01% | 1 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $28 | $23.45 | +19.40% | 4 | Mar 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $4.5 | $1.90 | +136.84% | 1 | Nov 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $16 | $5.45 | +193.85% | 1 | Sep 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Perform | n/a | $511.28 | - | 3 | Apr 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $60 | $0.41 | +14,609.49% | 2 | Nov 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Perform | n/a | $197.10 | - | 2 | Nov 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Perform | n/a | $5.98 | - | 1 | Sep 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $100 | $36.25 | +175.86% | 1 | Jun 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Market Perform | n/a | $72.20 | - | 5 | Sep 12, 2018 |
TransMedics Group
Oct 29, 2024
Maintains: Outperform
Price Target: $200 → $125
Current: $88.00
Upside: +42.04%
Abbott Laboratories
Oct 8, 2024
Initiates: Outperform
Price Target: $130
Current: $114.27
Upside: +13.77%
TriSalus Life Sciences
Sep 16, 2024
Initiates: Outperform
Price Target: $10
Current: $3.95
Upside: +153.16%
Edwards Lifesciences
Sep 12, 2024
Maintains: Outperform
Price Target: $90
Current: $70.58
Upside: +27.51%
Artivion
Aug 9, 2024
Maintains: Outperform
Price Target: $25 → $30
Current: $26.53
Upside: +13.08%
Nyxoah
Aug 7, 2024
Maintains: Outperform
Price Target: $15 → $13
Current: $9.54
Upside: +36.27%
iRhythm Technologies
Aug 2, 2024
Maintains: Outperform
Price Target: $165 → $145
Current: $76.15
Upside: +90.41%
Integer Holdings
Jul 16, 2024
Initiates: Outperform
Price Target: $135
Current: $128.21
Upside: +5.30%
ResMed
Jun 25, 2024
Downgrades: Perform
Price Target: n/a
Current: $247.76
Upside: -
AtriCure
Apr 23, 2024
Upgrades: Outperform
Price Target: $32
Current: $29.10
Upside: +9.97%
Feb 22, 2024
Downgrades: Perform
Price Target: n/a
Current: $5.19
Upside: -
Nov 15, 2023
Maintains: Outperform
Price Target: $42 → $30
Current: $13.21
Upside: +127.10%
Sep 6, 2023
Initiates: Outperform
Price Target: $70
Current: $87.87
Upside: -20.33%
Aug 8, 2023
Maintains: Outperform
Price Target: $24 → $30
Current: $14.47
Upside: +107.33%
Jun 23, 2023
Maintains: Outperform
Price Target: $16 → $10
Current: $0.46
Upside: +2,073.91%
May 16, 2023
Initiates: Outperform
Price Target: $97
Current: $86.60
Upside: +12.01%
Mar 6, 2023
Reiterates: Outperform
Price Target: $28
Current: $23.45
Upside: +19.40%
Nov 29, 2022
Initiates: Outperform
Price Target: $4.5
Current: $1.90
Upside: +136.84%
Sep 24, 2021
Initiates: Outperform
Price Target: $16
Current: $5.45
Upside: +193.85%
Apr 21, 2021
Upgrades: Perform
Price Target: n/a
Current: $511.28
Upside: -
Nov 17, 2020
Upgrades: Outperform
Price Target: $60
Current: $0.41
Upside: +14,609.49%
Nov 3, 2020
Upgrades: Perform
Price Target: n/a
Current: $197.10
Upside: -
Sep 15, 2020
Initiates: Perform
Price Target: n/a
Current: $5.98
Upside: -
Jun 24, 2020
Initiates: Outperform
Price Target: $100
Current: $36.25
Upside: +175.86%
Sep 12, 2018
Upgrades: Market Perform
Price Target: n/a
Current: $72.20
Upside: -